Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial | Zendy

David M. Asmuth | Zendy; Robert L. Murphy | Zendy; Susan L. Rosenkranz | Zendy; Juan J.L. Lertora | Zendy; Shyam Kottilil | Zendy; Yoninah Cramer | Zendy; Ellen S. Chan | Zendy; Robert T. Schooley | Zendy; Charles R. Rinaldo | Zendy; Nathan M. Thielman | Zendy; Xiaodong Li | Zendy; Sharon M. Wahl | Zendy; Jessica Shore | Zendy; Jennifer Janik | Zendy; Richard A. Lempicki | Zendy; Yaa Simpson | Zendy; Richard B. Pollard | Zendy

Open Access

Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial

Author(s) -

David M. Asmuth,

Robert L. Murphy,

Susan L. Rosenkranz,

Juan J.L. Lertora,

Shyam Kottilil,

Yoninah Cramer,

Ellen S. Chan,

Robert T. Schooley,

Charles R. Rinaldo,

Nathan M. Thielman,

Xiaodong Li,

Sharon M. Wahl,

Jessica Shore,

Jennifer Janik,

Richard A. Lempicki,

Yaa Simpson,

Richard B. Pollard

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/652420

Subject(s) - tolerability , pegylated interferon , medicine , human immunodeficiency virus (hiv) , hepatitis c virus , interferon alfa , virology , hepatitis c , interferon , clinical trial , immunology , virus , viral disease , adverse effect , ribavirin

To our knowledge, the antiviral activity of pegylated interferon alfa-2a has not been studied in participants with untreated human immunodeficiency virus type 1 (HIV-1) infection but without chronic hepatitis C virus (HCV) infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research